To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.
To investigate the real-world efficacy and safety of Sacituzumab govitecan for HER2 negative metastatic breast cancer patients in China.
Breast Cancer Metastatic
PFS, Progression-Free Survival, from enrollment to progression or death (for any reason),assessed up to 100 months
Objective Response Rate, Ratio of CR and PR in all subjects, from enrollment to progression or death (for any reason), assessed up to 100 months|DoR, Duration of Response, The first evaluation of CR or PR to progression or death (for any reason),assessed up to 100 months|OS, Overall Survival, from enrollment to death (for any reason).assessed up to 100 months
adverse event, Adverse events are described in terms of CTC AE 5.0, from enrollment to 30 days after the last dose administrate
This study will conduct a multicenter, open, prospective clinical trial to investigate the real-world efficacy and safety of Sacituzumab govitecan for HER2 negative metastatic breast cancer patients in China.